Epidemiology
Since FIV was discovered in 1986, serological studies have demonstrated that it is endemic in domestic cat populations worldwide; the seroprevalence of FIV is highly variable between regions, with estimates of 1-14% in cats with no clinical signs and up to 44% in sick cats. 10, 11 Sick adult cats, male cats and free-roaming cats are most likely to be infected. 12 The major route of natural transmission is via biting. 13 Vertical transmission and transmission between cats in stable households is relatively uncommon.
Transmission from mother to kittens may occur but only some offspring become persistently infected, the proportion depending on the viral load of the queen during pregnancy and birth. If the queen is acutely infected, up to 70% of the kittens may become infected. If the seropositive queen is healthy, few kittens will be infected. 14, 15 Although neither oronasal nor venereal spread has been documented in nature, cats can be infected experimentally by virus inoculation into the nose, mouth, vagina and rectum, and virus can be recovered from semen after natural and experimental infection. 16, 17 Queens may be infected at mating if bitten by an infected tom cat.
Pathogenesis
The major targets for FIV infection are activated CD4+ T lymphocytes. These cells typically function as T helper cells, which have a central role in immune function, facilitating the development of humoral and cell-mediated immunity. The FIV envelope glycoprotein gp120 binds to a primary receptor on the cell surface, the CD134 molecule. 18, 19 The viral reverse transcriptase that mediates transcription of the RNA genome into a DNA copy (or provirus) is error-prone and lacks a proofreading function; thus FIV mutates rapidly and displays great genetic diversity. Viral variants may evade immune detection and hamper the development of molecular diagnostic techniques and vaccines.
Infections become latent when a cell has integrated a provirus copy but does not produce virus particles -unless the cell becomes activated. Latently infected cells represent a 'reservoir' of infection that is not reached by neutralising antibodies, posing an obstacle for effective vaccination.
In the first few days after experimental infection, FIV replicates in dendritic cells, macrophages and CD4+ T lymphocytes, and within 2 weeks appears in the plasma. Both the virus levels in plasma and proviral DNA in the blood mononuclear cells increase, reaching a peak 8-12 weeks after infection. During this period, mild to moderate clinical signs such as anorexia, depression and fever may be observed. These conditions usually subside rapidly; in contrast, signs such as generalised lymphadenopathy, due to increased numbers and size of active germinal centres in the lymph nodes, may persist for weeks or months. The decrease in plasma viral load marks the beginning of the so-called 'asymptomatic' phase that can last for years (and may be lifelong). It is assumed that viral replication is controlled by the immune response, and during this phase the infected cat remains free of clinical signs.
The final outcome following FIV infection is variable. During the asymptomatic phase the plasma virus load is stable, but there is a progressive decline in CD4+ T lymphocyte numbers, resulting in a decreased CD4:CD8 T lymphocyte ratio. 20 In a proportion of infected cats this leads to a functional immunodeficiency, clinical signs of acquired immunodeficiency syndrome (AIDS) and death.
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Latently infected cells represent a 'reservoir' of infection that is not reached by neutralising antibodies, posing an obstacle for effective vaccination.
If the queen is acutely infected, up to 70% of the kittens may become infected. If the seropositive queen is healthy, few kittens will be infected.
FIG 1 Global distribution of feline immunodeficiency virus subtypes or clades.
Courtesy of Margaret J Hosie
Immunity
Passive immunity
In natural infections, the efficacy of colostral immunity is not known. Experimentally, susceptible kittens have been protected after passive transfer of antibody in response to challenge with laboratory-adapted isolates of FIV. 21 However, this may not apply to challenge with virulent field strains, and indeed enhanced infection was seen after transfer of antibodies from cats immunised with an experimental vaccine, indicating a fine balance between neutralising and infectionenhancing antibodies. 22
Active immune response
Cats infected with FIV remain persistently infected despite mounting antibody and cellmediated immune responses. Feline immunodeficiency virusspecific CD8+ cytotoxic T cells are detected in the blood within 1 week of infection. 23 Coincident with the peak of viraemia, anti-FIV antibodies, including virus neutralising antibodies, appear in the plasma. 24 They generally appear from 2-4 weeks after infection, but seroconversion may be delayed in cats exposed to low virus doses. 25 Antibodies recognising Env appear earlier than those against the Gag protein p24. 26 
Clinical signs
Most clinical signs are not directly caused by FIV, so it is vital to check for the underlying cause of the presenting clinical signs. In many cases, clinical signs will be the result of a secondary infection that should be identified and treated (see later). The virus itself is responsible for immunodeficiency (making the cat more susceptible to secondary infections and neoplasia) or immune stimulation (resulting in immune-mediated disease). In rare cases, FIV can cause neurological disease.
In the first weeks to months after infection, clinical signs lasting for a few days to a few weeks may be seen. These may include mild fever, lethargy and peripheral lymphadenopathy. 27 Haematology may reveal a neutropenia. 28 Infected cats then generally remain healthy before problems associated with immunodeficiency develop; 29 this asymptomatic period will last for years in most cases, and some cats will never develop FIV-related clinical signs. 30 Disease is often not seen until later in lifegenerally 4-6 years of age or older.
Immunodeficiency and/or immunostimulation most frequently appear in the form of chronic gingivostomatitis, chronic rhinitis, lymph adenopathy, immune-mediated glomerulo nephritis and weight loss ( Fig 2) .
Many concurrent viral, bacterial, fungal and protozoal infections have been reported in FIV-infected cats. 31, 32 Unusual or severe parasitic skin disease (eg, demodicosis, pediculosis) or tumours should alert the clinician to the possibility of FIV infection. Various neoplastic conditions, such as B cell lymphosarcomas, myeloproliferative disease and squamous cell carcinoma, have been reported in association with FIV infection. 33 Chronic gingivostomatitis is one of the most common presenting signs in FIV-infected cats, and impairs the cat's quality of life ( Fig 3) . 34 As confirmed by experimental infections with neurovirulent strains, central nervous system involvement and peripheral neuropathy are early subclinical events, often associated only with altered forebrain or peripheral nerve electrical activity. 35 In contrast, immunochromatography tests detect only antibodies recognising short peptides from the transmembrane protein.
In Western blots, purified FIV is first separated by gel electrophoresis into its constituent proteins, and the individual FIV proteins are detected by antibodies. 45 Both ELISA and immunochromatography tests are generally appropriate, but have limitations (see box on page 579).
✜ CD4+ and CD8+ lymphocytes
It is possible to stage the level of immune dysfunction by determining the CD4+ and CD8+ lymphocyte counts. However, due to the complexity of these assays, and the fact that in a clinical situation pre-infection values are not available, these tests are not clinically useful.
disrupted sleep patterns, impaired learning and paresis have also been reported. 37 Reproductive failure occurs in infected cats and is associated with PCR-positive placental and fetal tissues. 38 Renal involvement arising from glomerular and tubulointerstitial lesions associated with severe proteinuria is frequent in FIV-infected cats. Renal damage is caused possibly by the virus, together with renal immune deposits. 39 Polyclonal B cell activation sustains hyperglobulinaemia and high levels of circulating immune complexes and autoantibodies. 40, 41 Diagnosis Direct detection methods ✜ Virus isolation Virus isolation is a reliable diagnostic method but is laborious and not used routinely. Peripheral blood lymphocytes from fresh heparinised blood samples are co-cultivated with primary feline T cells for 2-3 weeks, and the presence of virus is confirmed by measuring the levels of viral core proteins in the culture fluids. ✜ Polymerase chain reaction Assays that detect proviral DNA are available, but vary in performance and may be inferior to serological tests, with sensitivities and specificities ranging from 40-100% [EBM grade I]. 42 
E B M r a n k i n g u s e d i n t h i s a r t i c l e
The asymptomatic period will last for years in most cases, and some cats will never develop FIV-related clinical signs.
Disease is often not seen until later in life -generally 4-6 years of age or older.
Discrepant PCR/serology results
As well as strain variation leading to discrepant results (see text), discrepancies may arise when serology and PCR are compared: ✜ Seropositive/PCR negative results may be explained by the presence of an FIV subtype not recognised by the PCR, rather than by the absence of FIV infection. This aspect is important if a cat has been vaccinated against FIV abroad.
✜ Seronegative/PCR positive results may also be found when cats living in close contact with FIVinfected seropositive cats become provirus positive without developing antibodies or disease. 44 Such cats are infected and will usually seroconvert weeks to months later. 
Management of FIV-infected cats
Positive results in a low-prevalence population
The diagnostic specificity of ELISA and immunochromatography tests is below 100%, which is important when healthy cats test positive in lowprevalence populations. For example, a prevalence in a population of 1% should result in one true-positive FIV test per 100 cats, and a diagnostic test specificity of 99% would result in one false-positive result in the same 100 cats. This gives two positive results in 100 cats, only one of which is correct (positive predictive value equal to only 50%
). Any positive result in a lowprevalence population (eg, young, indoor, pedigree cats) must therefore be confirmed -for example, by Western blot. A positive result in a cat from a high-risk group (eg, a free-roaming, aged, entire male) is likely to be correct, because the frequency of true positives will exceed that of false positives in this group. 
Negative results in a low-prevalence population
Seropositive kittens
Kittens born to FIV-infected queens may test seropositive as a result of passively acquired maternal antibodies. Such kittens should be retested after about 16 weeks of age, by which time maternal antibody should have disappeared, such that a positive result is indicative of an FIV infection. However, in rare cases antibodies may persist for up to 6 months, and a kitten testing seropositive at 16 weeks should be retested 2 months later. 46 If it still tests positive, the kitten is infected. If a definitive result is required earlier, PCR may be employed to detect virus-negative kittens; a blood sample from the queen should be tested in parallel to ensure that the PCR can detect the infecting strain.
Vaccine versus field strains of virus
I n t e r p re t a t i o n o f s e ro l o g y t e s t s Supportive treatment
If FIV-infected cats are sick, prompt and accurate diagnosis is important to allow early intervention. Many respond well to appropriate medication, although a longer or more aggressive course of therapy (eg, with antibiotics) may be needed than in uninfected cats. Some clinicians report benefits with corticosteroids and other immunosuppressive drugs in FIVinfected cats with chronic stomatitis, but their use is controversial because of side effects. Griseo fulvin has caused bone marrow suppression and should not be used. 51 Filgastrim (granulocyte colony-stimulation factor), a recombinant human cytokine (rHuG-CSF), has been used in cats with profound neutropenia. It can increase neutrophil counts, but may also lead to an increase in virus load [EBM grade III]. 52, 53 Erythropoietin is available as the recombinant human product and is used effectively in cats with non-regenerative anaemia due to endogenous erythropoietin deficiency in chronic renal failure. Cats with FIV treated with human erythropoietin (100 IU/kg SC q48h) showed a gradual increase in red and white blood cell counts [EBM grade IV]. 53 No increase in virus loads was observed, indicating that human erythropoietin can be used safely.
Insulin-like growth factor-1 is marketed as a recombinant human product and induces thymic growth and stimulates T cell function. Treatment resulted in a significant increase in thymus size and thymic cortical regeneration, replenishing the peripheral T cell pool in experimentally FIV-infected cats [EBM grade III]. 54 It could be considered in young FIVinfected cats, but there have been no studies to demonstrate efficacy in field cases.
Antiviral therapy
Most of the antiviral drugs that are discussed here are licensed for treating HIV infection in humans. Unfortunately, many of the antivirals used in humans are toxic to cats or ineffective.
AZT AZT (3'-azido-2',3'-dideoxythymidine) is a nucleoside analogue (thymidine derivative) that blocks the retroviral reverse transcriptase. AZT inhibits FIV replication in vitro and in vivo; it can reduce plasma virus load, enhance cats' immunological and clinical status, and improve quality of life. In a placebo-controlled trial, AZT improved stomatitis in naturally infected cats [EBM grade I]. 55 The appropriate dosage is 5-10 mg/kg q12h PO or SC. The higher dose should be used carefully as side effects can develop. For SC injection, the 580 JFMS CLINICAL PRACTICE lyophilised product should be diluted in isotonic sodium chloride solution to prevent local irritation. For PO application, syrup or gelatine capsules (dosage/weight calculated individually for each cat) can be given.
During treatment, a complete blood count should be performed weekly for the first month, because non-regenerative anaemia is common, especially at higher doses. If the values are stable, monthly checks are sufficient. Cats with bone marrow suppression should not be treated. Studies of FIV-infected cats treated for 2 years showed that AZT is well tolerated. Some cats may develop a mild decrease in haematocrit in the first 3 weeks, which resolves even if treatment is continued. If haematocrit drops below 20%, treatment should be discontinued, and anaemia then usually resolves within a few days. As in HIV, AZT-resistant mutants of FIV can arise as early as 6 months after the start of treatment.
AMD3100
AMD3100 belongs to the new class of bicyclams that act as selective antagonists of the chemokine receptor CXCR4. This molecule is the main co-receptor for T cell lineadapted HIV strains and, when blocked with AMD3100, virus entry is inhibited. Feline immunodeficiency virus also uses CXCR4 for virus entry. 56, 57 AMD3100 is not licensed as an antiviral compound but it is effective against FIV in vitro. In a placebo-controlled doubleblind study, in which naturally FIV-infected cats were treated (0.5 mg/kg q12h SC for 6 weeks), the drug caused a statistically significant improvement in clinical signs and a decreased proviral load. Side effects were not noted [EBM grade I]. 58 Interferons Feline interferon-omega was recently licensed for veterinary use in some European countries and Japan. Interferons are antiviral, immunomodulatory and anti-tumour cyto kines, which are species-specific; feline interferonomega can therefore be used for the duration of a cat's life without inducing antibody. Also, in contrast to the experience in human subjects, side effects have not been reported in cats. This cytokine is active against FIV in vitro, but in the only controlled study performed in field cats, no significantly improved survival rates were evident [EBM grade 1]. 59 Human interferon-alpha induces an antiviral state in cells and also has immunomodulatory effects. 60 Two treatment regimens have been published for the treatment of retroviral infections in cats [EBM grade III]. 61, 62 Whereas feline interferon-omega is available commercially and would be the appropriate cytokine to use, it is rather human interferon-alpha that
Prognosis for FIV-infected cats
The ABCD recommends that cats should never be euthanased solely on the basis of an FIV-positive test result. Some FIVinfected cats may live as long as uninfected cats [EBM grade III]; 30 however, they have a higher risk of developing clinical signs, principally due to secondary infection, immune-mediated disease or neoplasia. 12, 30, 48 The duration of the asymptomatic stage varies according to the infecting variant. 49 When cats are infected at a younger age, they are more likely to progress to an immunodeficient state [EBM grade III]. 50 has been reported to prolong the survival times of FIV-infected cats [EBM III]. 62
Immune modulators and interferon inducers
Immune modulators and interferon inducers are widely used medications in FIV-infected cats. There is no conclusive evidence from controlled studies that they have any beneficial effects on health or survival. Rather, a non-specific immune stimulation can lead to increased viral loads via the activation of latently infected cells, and hence disease progression. These products should not be used in FIV-infected cats.
Disease control in specific situations
Multi-cat households
The risk of FIV transmission is low in households with socially well-adapted cats. If one cat is diagnosed with FIV infection, all cats in that household should be tested. The virus is transmitted mainly during biting and fighting, and if no aggression occurs due to the stability of social and territorial structures, the probability of transmission is low. In followup studies, few additional cats seroconverted over many years. All cats should be neutered, and no new cats introduced, as this might disrupt the harmony, even between cats that have lived peacefully together for a long time.
If other infectious diseases are spreading in a multi-cat community, the risk of FIV transmission may also be higher. In that situation, isolation of seropositive cats should be considered.
Shelters
Feline immunodeficiency virus is an important consideration in rescue shelters as the prevalence of infection is particularly high in populations with a feral background and in male cats. The prevalence may be lower in pre-owned cats that have recently been relinquished, compared with sheltered stray cats.
The ABCD recommends that all cats should be tested. If this cannot be achieved, at least all sick cats should be tested, and euthanasia considered when the clinical problems relate to an advanced stage of FIV infection.
Serological tests do not reliably identify infected kittens under 6 months of age. A positive result does not confirm that the kitten is infected and it must be emphasised that it is not an indication for euthanasia. In this situation, diagnosis by PCR may be considered.
The ABCD recommends that in rescue shelters, seropositive cats should be housed individually (unless from the same household); as an absolute minimum, FIV-positive cats should be segregated from FIV-negative cats. Some shelters will home FIV-positive healthy cats to selected adopters who offer living environments where the risk of infection for other cats is minimal. Detailed counselling is required.
Breeding catteries
Usually, cats in breeding catteries are kept indoors and are tested annually, and hence FIV is rare. New cats should be tested before being introduced, and breeders using an external stud or allowing an external queen to visit their stud should request proof of FIV-negative status. Cats that have escaped and returned should be quarantined for 3 months, tested and returned to their group only if found to be seronegative.
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The risk of FIV transmission is low in multi-cat households with socially well-adapted cats.
There is no FIV vaccine commercially available in Europe. Experimentally, protection has been achieved by using several immunogens, including inactivated virus or infected cells, canarypox-based antigen expression in combination with inactivated cells and naked DNA. 63 The most successful so far have been whole inactivated virus preparations; one such vaccine has been on the market in the USA since 2002 and in Australia and New Zealand since 2004.
However, this vaccine's efficacy has not been tested against challenge with European field isolates and did not protect cats against a virulent UK primary FIV isolate [EBM grade III]. 64 Imported vaccinated cats might therefore not be protected against naturally occurring European isolates of FIV.
Va c c i n a t i o n Not recommended
The ABCD does not recommend the use of the FIV vaccine in Europe, because it invalidates the serological diagnosis of infections and may not protect against European isolates. 
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